NeoGenomics launches PanTracer Tissue and PanTracer Tissue HRD for advanced cancer diagnostics (ir.neogenomics.com)

• PanTracer Tissue covers over 500 genes with results in about 8 days.
• Optional HRD analysis provides BRCA status and genomic instability score for ovarian cancer.
• Assay replaces NeoComprehensive Solid Tumor and strengthens NeoGenomics' multiomics portfolio.

"NeoGenomics (NASDAQ: NEO) announced the launch of PanTracer Tissue, a solid tumor profiling assay covering over 500 cancer-related genes, with an optional HRD analysis for ovarian cancer including BRCA status and genomic instability score. Results are available in as little as 8 days. The offering replaces the previous NeoComprehensive Solid Tumor test and strengthens NeoGenomics' competitive position in multiomics cancer diagnostics."